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Abstract
Modern antibacterial drugs are quickly becoming insufficient for medical, agricultural
and veterinary use, and the drug design techniques used to supplement the supply are not able to
adequately and quickly produce enough effective candidates. We took a multi-pronged approach
to remedying this problem, including shifting the target mechanism from antibiotic drugs in
favor of anti-infective drugs, developing an AI which aimed to predict the interactions of small
molecule fragments with the target protein, and refining wet lab testing protocols in order to
make the drug design process holistically more efficient and effective. We have shown that there
is potential in this design space, as the design techniques are faster and more effective than those
previously used, and the drug candidates are promising as they undergo further testing. Research
into broader applications of this technology to other target proteins, and expansion of the AI’s
scope in specific applications will allow for fast and safe design of life-saving drugs.
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Chapter 1: Introduction
1.1 Background and Motivation
1.1.1 Antibiotic Resistance
Antibiotics are known as one of the most effective and successful drug therapies in all of
human history. They are a type of antimicrobial chemical that is meant to destroy and/or inhibit
the growth of bacteria to prevent and treat harmful infections. Their discovery has resulted in the
development of countless subsequent medical treatments, countless lives saved, and even some
diseases eradicated, such as smallpox. Paul Ehrlich and Alexander Fleming are credited with the
development of the first natural and synthetic antibacterial drugs, Salvarsan and Penicillin.
Ehrlich’s “magic bullet” theory is what guided his search for a drug that could target diseasecausing organisms without harming the rest of the body. His theory was based on synthetic
laboratory dyes that were used to only stain microbes and not other tissues (Aminov et al, 2010).
These revolutionary drugs have since been used as a baseline for furthering research on and
development of bacterial infection treatment, our project will take a new approach.
While the development of antibiotics has saved millions of lives and improved overall
quality of life on Earth, there is a growing threat in the form of antibiotic-resistant bacteria.
Antibiotic-resistant infections are hard to treat and hard to prevent because antibiotic drugs
introduce a pressure that causes bacterial cells within a population to mutate their targeted sites
in order to survive the attack. This can happen with any kind of antibiotic and the rate of
mutation has begun to outpace the rate at which antibiotics are being tested and created, as the
process is both time and labor intensive.
One especially prominent type of antibiotic-resistant infection is infection by methicillinresistant strains of Staphylococcus aureus (MRSA) (Taylor, 2022). Staphylococcus aureus is a
gram positive bacteria that is commonly found on the skin and mucous membranes of humans.
When it enters deep tissue or the bloodstream, it can cause a variety of infections such as
gastroenteritis, meningitis, skin infections, and toxic shock syndrome which are typically treated
with first-line antibiotics: methicillin, amoxicillin and penicillin. When left untreated, MRSA can
cause severe complications and sepsis with a mortality rate between 20%-50% (CDC, 2019). In
2017, there were nearly 120,000 MRSA bloodstream infections in the United states with 20,000
associated deaths (CDC, 2019). While the number of overall bacterial infections is decreasing
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due to improved healthcare access and other factors, the number of antibiotic-resistant strains is
growing rapidly.
Attempts have been made to develop an alternative treatment for S. aureus, with little
progress so far. Some challenges for developing a stronger treatment against S. aureus include
poor understanding of pathogenic mechanisms, its multiple virulence factors, and the wide
variety of diseases it can cause (Proctor et al, 2012). Thus, there is an urgent need for a new
approach to treating S. aureus infections.
1.1.2 Sortase A
Gram-positive bacteria like S.aureus have a multitude of proteins displayed on the cell
surface that are very important to successful cell function and pathogenicity. Sortase A is one of
these proteins that anchors virulence factors to the outer membrane of S. aureus. It is a 206
amino acid, membrane-bound cysteine transpeptidase (Lu et al, 2007). Virulence factors are
molecules responsible for the infection of host tissues and for retaining bacteria cells within.
When Sortase A is in a dimer conformation, it is inactive. Therefore, the bacteria is unable to
express virulence factors and can’t invade the mammalian cell. When an activating molecule,
released by mammalian cells, binds to sortase A, it undergoes a conformational change from a
dimer into a monomer (Zhu et al, 2016). In this active monomer conformation, the bacteria can
now express virulence factors and invade mammalian cells.
Typically, surface virulence proteins contain an N-terminal signal peptide and a Cterminal sorting signal, and Sortase A is capable of catalyzing a transpeptidation reaction, which
is a reaction that links two protein chains together (Zhu et al, 2016). The LPXTG motif is part of
the sorting signal that will be first cleaved by the Sortase A. The resulting surface protein
intermediate is then covalently attached to the cell wall, a characteristic structure of Grampositive bacteria, displaying the protein on the microbial surface.
By inhibiting the dimerization of sortase A with a small molecule drug, it may be
possible to remove the anchored virulence factors from the surface of the cell and prevent its
entry into mammalian host cells.
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Figure 1. The sortase A protein on the surface of S. aureus exists as a dimer in its active
form, which allows for the anchoring of proteins to the outer surface of the bacterial cell wall (Lu
et al, 2007).
1.1.3 Current Drug Design Approaches
Current drug discovery methods are known to be time-intensive, labor-intensive, and
expensive. They are not capable of keeping up with the rapidly growing number of antibioticresistant bacteria strains. There are two major schools of drug design, physical mass chemical
testing and simulation based testing. The former has historically been more common, though its
presence is fading to more modern approaches (Mahdal et al, 2009). Modern testing takes years
to establish candidates, before even beginning clinical testing. There are several firms that have
established deep learning approaches for drug design have been successful in some aspects but
still have significant room to improve (Urbina et al, 2022). Both in terms of efficacy and safety,
the industry must progress in order to effectively combat the problem of antibiotic drug
resistance. Researchers from the Massachusetts Institute of Technology have shown notable
results using AI-driven drug screening for antibiotics rather than anti-infectives. They trained a
deep neural network model to analyze E.coli inhibition by introducing an established FDAapproved drug library supplemented with another natural compound library (Stokes et al, 2020).
Next, the researchers had the model sort through known antibiotic compounds from the Drug
Repurposing Hub to find a suitable broad-spectrum antibiotic for E.coli. This network model
performed well with a 55% accuracy given its limited parameters (Stokes et al, 2020).
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1.1.4 Flow cytometry for cell analysis
The invasion assay developed by Dr. Zhang’s lab performs cellular fluorescence
quantification using flow cytometry in order to establish a baseline quantification of S. aureus
infection of CHO cells before testing our target molecule. Flow cytometry measures the intensity
of fluorescently-stained cells and provides an absolute value for said measured light intensity.
This technology is very popular in molecular research and has numerous applications in
immunology, virology, molecular biology, cancer biology, and infectious disease monitoring.
Stained and preserved cell solutions are suspended in a buffered saline solution that runs through
the fluidics system within the cytometer where lasers measure the light intensity coming from
each individual particle (McKinnon et al, 2018).

Figure 2. Simplified diagram of flow cytometry analysis used for quantification of bacterial
invasion.
1.1.5 Real-Time PCR (qPCR)
Real-Time PCR (qPCR) is a nucleic acid amplification and detection technology that is
currently one of the most valuable tools in modern biological research as it is used in a wide
range of applications including diagnostics, research, biotechnology and medicine. This method
quantifies the presence and amount of a gene of interest within a sample well in real time.
4

Quantification is achieved through the inclusion of fluorescence reporter molecules and the gene
of interest itself is identified and amplified through the use of specific oligonucleotide primers.
For successful measurement, each sample well must have a certain amount of target
DNA, primers, fluorescent dye, dNTPs and taq DNA polymerase and each of these ingredients
play an important role. The target DNA sequence can be added in any form. Many biological
research applications will extract and purify this sample before PCR. Our project intended to
recognize a target sequence in S.aureus within infected chinese hamster ovary (CHO) cells
without purification.
Primers are short fragments of single-stranded DNA that are complementary to sequences
that flank the gene of interest. Taq DNA polymerase is an enzyme that attaches free floating
nucleotides (dNTPs) to growing DNA strands, the fluorescent dye is often an intercalating dye
that attaches to the newly formed sequence, and the qPCR machine will detect and quantify the
levels of fluorescence. A higher fluorescence signal means there are more copies of target DNA
successfully forming within the sample (Bio-Rad, “What is Real-Time PCR?”).
A qPCR machine amplifies the labeled target sequences by cycling between specific
temperatures over specific periods of time. The first step is denaturing where the machine will
heat the sample up to about 95℃ which is when double-stranded DNA will separate into single
strands. The second step is primer annealing and extension. The temperature is brought down to
50-60℃ where the primers will attach to both ends of the single-strand target sequence, and taq
DNA polymerase will add complementary dNTPs (free floating nucleotides) (Bio-Rad, “What is
Real-Time PCR?”).
The average qPCR run will have between 30-40 amplification cycles, each time the
amount of target DNA is amplified by 2^n copies. Fluorescence levels are measured during each
cycle but are only detected after a certain amount of DNA is reached (Cq value) and the
fluorescence is no longer background noise, after which the amplification happens exponentially.
The Cq value is inversely related to the initial amount of target DNA within a sample and
correlates to a number of target DNA copies in the sample. Low Cq values such as those around
29 cycles indicate larger amounts of the target sequence, while high Cq values indicate small
amounts (Ruiz-Villalba, 2021).
1.2 Literature Review
5

1.2.1 AI for drug design
Motivated by the slow and expensive process of traditional drug design, researchers are
eagerly pursuing AI and machine learning solutions. Most of the research is focused on the De
Novo drug design, with two primary goals: distribution-learning and goal-directed generation
(Blaschke, 2020). Distribution-learning is focused on creating molecules similar to given target
molecules, and goal-directed learning seeks to design molecules that satisfy the users’ specific
objectives. Many ML methods are used for drug design, to varying degrees of success. A
promising application is using recurrent neural networks to generate large amounts of molecules
and then using transfer learning and reinforcement learning as a way to filter results (Arús-Pous,
2020). Conditional Graph generation has also shown success, especially in its ability to
consistently generate valid outputs (Li, 2018). Because AI drug design is still in its infancy, we
will surely see many more methods tried in the coming years.
1.2.2 Drug testing
High-throughput screening (HTS) is one of the most popular and well-established
methods of drug design and testing. This method focuses on assaying and screening established
chemical, genomic, protein and peptide libraries with biological models at a large scale which
involves the use of robotics, liquid handling and advanced processing software. Cell-based
assays are the main way of testing these libraries and high-density arrays of microreaction wells
such as 96- or 384-well microtiter plates are typically how they are structured. Each
microcreaction well will contain a 2D cell monolayer culture and the addition of one chemical
from a library to be tested; the automated system in the form of robotic liquid handling
technology will then grow the culture and monitor the reactions within each well. “Hits” are
known as compounds that have produced the desired reaction within the microreaction well and
those are taken through more specific and quantitative testing. Using this method, it is possible to
screen up to 10,000 compounds a day (Szymanski et al, 2011) with the right amount of space and
financial support.
Small molecules refer to chemical compounds with “small” molecular weights, ranging
under 500 g/mol and 100 g/mol. These compounds and the vast libraries they make up are
routinely used in HTS due to their ability to easily cross the cell membrane (Yip et al, 2017).
Small molecule drug screening is a more specific type of HTS and can be split into two
6

categories: phenotype-oriented and target-based. Compounds in phenotype-oriented screens are
typically tested for their ability to induce a certain phenotype in biological models. Things such
as cell division alteration, metabolism, adhesion and viability are monitored using this type of
screening method. Target-based screening involves more direct targeting, for example a purified
compound would be tested for its ability to inhibit the function of certain proteins. Antibiotics
are tested mainly through target-based screens for toxicity and for every “hit” there will be
several counter and cross screens to validate the effectiveness of the compound (Yip et al, 2017).
1.3 Critiques of current approaches
1.3.1 AI for drug design
Most current applications of AI in this field are based around the De Novo drug design.
The AI is given free reign to design the drug from scratch. The danger in this is that the drug
being designed could potentially be toxic, or even fatal (Urbina, 2022). We argue that the best
use of AI would be using it to build off of a scaffold that has been developed beforehand through
rigorous wet lab testing, thus reducing the risk of severe side effects.
Furthermore it is critical that AI processes are carefully assembled. Current research is
largely into narrow applications of AI which must later be integrated into an effective unit. There
is immense danger here that ethical safety precautions which existed through human intervention
are simply unthinkingly removed as they are combined. The current approaches for a synthesis
of AI techniques must be interrogated to ensure that as they are brought together, the contexts
which make them acceptably safe in isolation are not broken.
1.3.2 Drug testing
High-throughput small molecule screening is one of the most commonly used methods
for developing drugs, but it can be expensive and time consuming especially considering the
growing threat of antibiotic resistance. This threat is not new, but is quickly becoming a crisis as
the inappropriate use of antibiotics in medical, veterinary and agricultural sectors within the last
few decades has pushed microbe populations to adapt and develop drug resistance at astonishing
rates(O’Neill, 2014). This is costly, current epidemiologic studies have shown that the economic
burden associated with antibiotic resistance is significant, each year in Europe and the United
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States such infections lead to 11 million additional hospitalization stays and over 20 billion
dollars in additional social and healthcare costs (David et al, 2021).
The rate at which new antibiotic drugs are being developed is not enough to keep up with
the ever-changing microbe populations that they target, researchers typically put in more effort
than it is worth and financial support for such experiments is decreasing in favor of alternative
drug testing methods. While HTS is known for its large scale testing methods and easy
programmability, it has several drawbacks such as cost, prolonged testing/implementation and
period of synthesis, and requires large amounts of space and human resources for maintenance
(David et al, 2021).
1.3.3 Zhang lab invasion assay
Though measurement of fluorescence intensity is a useful and accurate method of
quantifying the number of bacteria that were able to enter the CHO cells during the invasion
assay, it has some limitations. For example, adding fluorescent dye to bacteria is a relatively
labor-intensive step that is not guaranteed to label all bacterial cells properly. It is also difficult to
ensure that all bacteria have been labeled permanently. The instrumentation required to quantify
fluorescence intensity is also expensive and requires a significant technical background to
operate, making the invasion assay more costly and difficult to run (Jian et al, 2020).
1.4 Project Overview
Anti-infective drug approaches may be the answer to this call for a new bacterial
infection treatment approach. By preventing S. aureus from interacting with and invading
mammalian cells in the first place, they would no longer be able to proliferate using the host
cell’s machinery- thus, preventing severe disease (Alksne, 2000). Previous research has shown
that the protein called sortase A is integral to the entry of S. aureus into mammalian host cells.
Sortase A anchors surface proteins, such as virulence factors, to the bacterial cell wall that
interact with host tissues and activate bacterial invasion (Ton-That, 1999). By inhibiting sortase
A, surface proteins that interact with mammalian host cells will no longer be anchored to the
bacterial cell wall. Without these invasion proteins on its outer surface, S. aureus can no longer
enter host tissue, preventing infection (Bierne, 2002). Our goal is to drastically reduce the time
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required to design drugs that are capable of preventing bacterial infection, and to do this we
attacked the problem from multiple directions.
First we chose to focus on an anti-infective approach and develop a small molecule drug
using AI instead of manual human labor that could effectively inhibit sortase A and prevent
bacterial infection in vitro. And secondly, we aimed to improve the physical testing mechanisms
for these candidates, so that subsequent testing would be as efficient as possible. Existing
computing solutions are inefficient and require significant manual input, and thus are only
suitable for testing individual molecules. We sought to design a program that can be fully
automated and test large libraries of fragments in a relatively short amount of time. Our program
showed us the best performing small molecule fragments, which we then manually attached to
our scaffold using Chemdraw to create our proposed drug candidate.
The goal of our project is to test these predicted molecules in vitro using an invasion
assay established by Dr. Zhang’s lab (Lu et al, 2007), and also optimize this assay through the
implementation of quantitative polymerase chain reaction (qPCR) for analysis of drug efficacy.
We want to build a protocol that would decrease the amount of time needed to run the invasion
assay, allowing future researchers to assess drug efficacy faster and more easily. Our data so far
is promising but needs more testing to reach a definitive conclusion.
By using qPCR instead of fluorescence detection, we hope to completely eliminate the
need for a time-consuming fluorescence labeling step. Doing so would reduce the cost of the
instrumentation needed for quantification too, as qPCR machines are relatively inexpensive
compared to FACS machines and have often been purchased by many laboratories already
anyways (Takamatsu, 2017). Finally, we want our protocol to increase the sensitivity of the
invasion assay by detecting bacteria at the transcriptomic level.
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1.5 Backup Plan
1.5.1 AI
If our program had given us inaccurate results in our testing, we would have re-evaluated
the tools we were using and either modify the implementation, or simply use different tools. We
would look first to other tools in the Autodock family. Autodock 4 is a well-established system
for simulating ligand-protein interactions, and implementing it instead of Vina would not require
a significant change to our architecture (Morris, 2009). We could also have reduced the scope of
our AI in order to have a smaller search space. Though this would have had affected the quality
of our results, it would still have acted as a strong proof of concept for our AI model.
1.5.2 Invasion assay optimization
In the event that we are unable to successfully implement qPCR into the invasion assay,
we planned to investigate the possibility of quantifying the amount of bacteria that invaded the
CHO cells using a gram-positive-specific dye. We would follow the original invasion assay
protocol, but rather than using a fluorescent stain before the invasion, we would use a UV-Vis
stain after the invasion was complete. CHO cells would be lysed after the invasion using a gentle
homogenizer, while the S. aureus cells would be kept intact. The remaining S. aureus cells
would be spun down, stained using a form of gram stain, and quantified using a plate reader.
1.6 Significance
Anti-infective drug design is a fairly new term for the process of developing drugs that
inhibit the infectious mechanisms of bacterial cells and other harmful microbes. This type of
drug design addresses the growing threat of antibiotic-resistant bacterial infections which are
responsible for roughly 700,000 deaths worldwide (O’Neill, 2014) and is showing no signs of
slowing down without a major shift in prevention tactics. Our project aims to address this need
and even speed up the process. Currently, the average amount of time needed to push a new drug
from the discovery phase to market authorization is 12 years, computer-aided drug design is
capable of cutting this number down by several years because it greatly reduces the need for
costly drug design and testing methods such as high-throughput screening (David et al, 2021).
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1.7 Team and Management
1.7.1 Interdisciplinary team management
Our team was made up of three computer science and engineering (COEN) and two
bioengineering (BIOE) students. The COEN half of the group was tasked with designing the AI
program, while the BIOE half was tasked with optimizing the invasion assay used to test the
drug molecules generated by the AI program. Though the two end products were separate, they
were unified in the goal of making the process of drug design more efficient, and design choices
of each were influenced by information from the other.
1.7.2 Timeline
Table 1. Project timeline for the academic year
Fall Quarter

Winter Quarter

Spring Quarter

COEN

● Molecular
docking
● AI brainstorming

● Developing AI
program
● Becoming familiar
with Chemdraw and
AMDock

● Finish AI
program
● Predict fragments

BIOE

● Invasion assay
optimization
brainstorming
● Begin CHO cell
culture

● Zero experiment
● qPCR primer design
● Initial qPCR testing

● Establish and
optimize qPCR
protocol
● Test AI-generated
molecule

Both

● Literature review

-

● Conference
presentation
● Thesis writing

1.7.3 Materials and Budget
Our team was granted a total of $2,500 for this project ($1,000 for bioengineering
materials and $1,500 for computer science and engineering materials). We also utilized materials
already available in Dr. Zhang’s lab.
Table 2. Project budget breakdown
Material

Quantity

Price

11

Laptops (Lenovo IdeaPad 3)

3

$500

ChemDraw

1 license

In storage

0.25% Trypsin-EDTA (Gibco)

3

$46.98

FBS, Heat Inactivated (Gibco)

500 mL

$654

10x PBS, pH 7.4 (Gibco)

500 mL

In storage

DMEM, High glucose, GlutaMAX Supplement (Cytiva)

10 x 500 mL

In storage

Trypan blue, 0.4% (Rs’ Science)

1 x 10 mL

In Storage

DMSO (Fisher Scientific)

1 x 15 mL

In storage

TSB Media Powder

100 g

In storage

Gentamicin

1 x 15 mL

In storage

Penicillin/Streptomycin

1 x 15 mL

In storage

CHO cells

5 x 1 mL vials

In storage

RN4220 cells

1 x 1 mL

In storage

Triton X-100 (Bio Basic)

500 mL

In storage

Nuclease-free water, DEPC-treated (Ambion)

1L

In storage

SYBR Green qPCR Master Mix (Bio-Rad)

2 x 1 mL

$152.29

Lysozyme (Bio-Rad)

1 x 500 µL

In storage

16S rRNA primers (IDT)

2 x ~200 µL

$21.50

S. aureus primers, SaQuant (IDT)

2 x ~200 µL

$21.50

Sortase A primers (Elim Bio)

2 x 50 µL

$7.86

Sortase B primers (Elim Bio)

2 x 50 µL

$7.86

Agarose powder (Bio-Rad)

1 x 125 g

In storage

Gelite™ Safe DNA Gel Stain (AAT Bioquest)

1 x 500 µL

In storage

Hemocytometer (Rs’ Science)

1

In storage

Conical vials, 15 mL (CELLTREAT)

10 x 50/PK

In storage

Conical vials, 50 mL

500 tubes

$369
12

10 cm petri dishes, tissue-culture treated

25 x 20/PK

In storage

Pipette tips, 1000 µL, United Scientific Supplies

2 x 500/PK

$41.08

Pipette tips, 20 µL, United Scientific Supplies

1 x 1000/PK

$27.48

Pipette tips, 10 µL, United Scientific Supplies

1 x 1000/PK

$20.66

Serological pipette tips, 5 mL

1 x 200/PK

$36.70

Serological aspirating pipette tips, 5 mL

8 x 20/PK

In storage

96-well PCR plates (ThermoFisher)

1 x 25/PK

$138

Optical plate covers (Applied Biosystems)

1 x 25/PK

$89.50

Cryovials, 2 mL ()

2 x 50 tubes

$27.10

Eppendorf Tubes, 1.5 mL

200 tubes

In storage

CS&T RUO Beads

50 tests

$124

Globe Scientific Glass Culture Tubes

250/box

In storage

CellTreat Cell Strainer

70 µm

In storage
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Chapter 2: Artificial Intelligence Platform Development
2.1 Design Goals
The cornerstone of the design philosophy of this project is anchoring the machine
computation in human biological understandings. Both the target protein Sortase-A and the
“scaffolding” drug candidates are built from products of traditional molecular biological
engineering research. This has two-fold benefits: first it minimizes necessary research space as
the AI is able to more efficiently predict drug candidates. Given the expense of computing time
this is a worthwhile investment, both in time and money. Second, by building the drug
candidates from scaffolds of known safety and effectiveness, the chances of compounds with
unpredictable side effects can be reduced. This philosophy arises from the collected experience
of our advisors in drug design.
Most AI systems are inherently uninterpretable, and therefore difficult to prove the
reliability of. This software is no exception. Both of these traits carry ethical risks which our
system must be designed around. The limited interpretability of internal AI mechanisms and
strategies means that the AI cannot have its processes verified for thoroughness or freedom from
biases. While a simpler system can be manually checked by a human, ML operations are too
deeply abstracted for this to be possible. Biases which creep into the system are therefore
difficult to detect. This is the danger of De Novo drug design, which is the unfettered design of
drugs by AI systems. While some degree of De Novo design is necessary to create an AI,
minimizing this will create the safest system possible.
Biases in the training data and docking software are likely to creep into the system.
Testing in other analogous BioAI designs has shown the ability for dangerous scaffolds to
produce similarly dangerous results (Urbina, 2022). However, the pursuit of perfection cannot be
allowed to get in the way of progress. It is relevant here that there are likely a myriad of
compounds which would be effective, and it is not necessary to find them all, or the optimal
candidate. A sufficiently effective anti-infective drug is the goal of this project. So while a set of
candidates to be tested for side effects is needed, biases which prevent a subset of candidates
from being detected will have a negligible impact. With sufficient wet-lab testing and care in the
post-AI design of drugs, the risks will therefore be acceptably minimized.
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2.2 Software Architecture
The AI operates on the input data of small-molecule fragments. As shown in figure 3, the
first step is the selection of an input library. Several preprocessing steps are undertaken in order
to extract the files from their compressed library file. Then they are converted into a workable
format. Finally, the real work can begin. Each individual fragment is scored on its stability and
undergoes simulated attachment to the target protein. The best performing fragments are
outputted, which is then manually sent to chemdraw to be combined and further tested.

Figure 3. High level architecture of our software implementation
2.3 Software Components
There were several software modules used in the construction of the BioAI. Autodock
Vina is the backbone of our project, as it is the framework we use to simulate the docking of
fragments with Sortase A. OpenBabel is the tool which we used in order to convert input
chemical files to workable types, allowing the rest of the process to occur.
Several helper pieces of software were important to the design process of the AI,
although they are not directly included in the platform. PyMol was critical, as it allowed the
viewing of 3-dimensional representations of the molecular structures. Although this view is not
directly tied to the computation of binding, it allows for useful human checks of the AI’s output.
AMDock is a popular docking simulator, which we used to verify our results. Chemdraw
allowed the creation of virtual representations of drug candidates from fragments and scaffold
for further testing.
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We used several drug fragment libraries, selecting those which were recommended by
our advisors. The Maybridge Corporation’s Screening fragments (~ 300 fragments) and General
fragment library (~ 400 fragments) as well as Life Chemicals’ General fragment library (~ 500
fragments) were our main sources of data.
2.4 BioAI Results
After screening fragments from the Maybridge Screening fragments library, the
Maybridge General fragment library, and the Life Chemicals General fragment library, we
selected the top 3 fragments and verified their affinities with Sortase A using AMDock. Then,
using Chemdraw, we constructed our drug candidate, exported the chemical structure file, and
simulated the chemical docking with Sortase A. Our goal for our drug candidate was for it to
have a higher affinity than the candidate discovered by previous groups through wet lab testing.
Our result was that our drug candidate’s affinity exceeded the previous group’s by 30.4%. Our
goal in terms of efficiency was to have our program be able to screen large libraries of fragments
in a relatively short amount of time compared to existing programs. We found that our platform
can test a fragments’ binding affinity with Sortase A in an average of 30 seconds, a huge
improvement compared to AMDock, which takes about 4 minutes on average to perform
comparable tests.

Figure 4. The time required to test the binding affinity of a single fragment with the
target protein using 3 different methods: Wet Lab testing, AMDock, and our program
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As shown in figure 4, testing fragments using wet lab testing takes a minimum of 15
hours. Testing fragments using AMDock takes an average of 4 minutes. Our program takes an
average of only 30 seconds.

Figure 5. The time required to test the binding affinity of a single fragment with the
target protein using AMDock as compared with our program

Figure. 6. The chemical structure of our best performing molecule
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Figure. 7. Visualization via Pymol of our best performing molecule

Figure. 8. A 3-dimensional representation of the best performing molecule docked with
Sortase A. The molecule can be seen at the bottom right corner of the image.
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Chapter 3: Invasion Assay Optimization
3.1 S. aureus culture
A strain of S. aureus called RN4220 was used for infection of CHO cells in the invasion
assay. This strain has been genetically modified through the use of chemicals and radiation so
that it can accept foreign plasmids for cloning (Nair et al, 2011). RN4220 was obtained from Dr.
Zhang’s lab, and was grown on petri dishes coated in tryptic soy broth (TSB) agar. The RN4220
stock was removed from the -80oC freezer and briefly thawed, then streaked on an agar plate in a
zigzag pattern using an inoculation loop. The plate was wrapped in parafilm and incubated
upside down at 37oC overnight, and then stored in a 4oC fridge.
3.2 CHO cell culture
3.2.1 Recovery
CHO cells were recovered from liquid nitrogen storage before performing the invasion
assay. They were thawed by warming for 60 seconds in a 37oC water bath. It is critical to ensure
that the time spent in the 37oC water bath is kept to a minimum, as the dimethyl sulfoxide
(DMSO) present in the cryopreservation media is toxic to cells. Thawed cells were slowly added
to a 15 mL falcon tube containing 5 mL of complete growth medium (DMEM containing 10%
fetal bovine serum (FBS)). The tube was then centrifuged at 3000 rpm for 1 minute to collect the
cells at the bottom. The supernatant was removed, and the cell pellet was resuspended in 2 mL of
growth medium. The resulting cell suspension was then added to a 10 cm plate containing 5 mL
of growth medium.
3.2.2 Passaging
CHO cells were cultured in a growing medium consisting of DMEM with 10% FBS. FBS
concentration was changed multiple times throughout the project with the goal of optimizing cell
growth, but ultimately 10% proved to be the optimal concentration. While antibiotics such as
penicillin and streptomycin are typically added to mammalian cell culture media, we
intentionally left them out of our media since they would prevent bacterial infection during the
invasion assay. Prior to performing the invasion assay, CHO cells were incubated at 37oC and
5% CO2, and passaged every 3-4 days after reaching ~80% confluence.
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To passage a 10 cm plate of CHO cells, the old growth medium was first removed
through aspiration. 4 mL of PBS was then added to the plate, which was subsequently tilted five
times to remove leftover serum and dead cells. The PBS was then aspirated and replaced with 2
mL of 0.25% Trypsin-EDTA. The plate was incubated at 37oC for 3 minutes to allow sufficient
time for cell detachment. After incubation, 5 mL of growth medium was added to the plate to
neutralize the trypsin and help wash off cells that may not have fully detached yet. The resulting
cell suspension was collected and centrifuged in a 15 mL falcon tube at 3000 rpm for one
minute. The cell pellet was resuspended in 3 mL of growth medium and split evenly between
three 10 cm plates each containing 6 mL of growth medium.
Due to the lack of antibiotics in our growth medium, we did see occasional bacterial
contamination in our cell culture plates (Appendix A). To address this, we began adding
penicillin and streptomycin to a final concentration of 50 µg/mL during the spring quarter. The
growth medium containing antibiotics was removed approximately one passage before
performing the invasion assay and replaced with growth medium containing no antibiotics.
3.2.3 Cryopreservation
To ensure that we always had cells throughout the project, we routinely expanded and
froze down aliquots of our CHO cells. To freeze one 10 cm plate of cells, the cells were
trypsinized and collected using the same protocol used for passaging. However, the cell pellet
was instead resuspended in 1 mL of freezing medium (DMEM with 10% FBS and 20% DMSO).
DMSO decreases the electrolyte concentration in the medium surrounding the cells to help
prevent crystallization during freezing, which can lead to apoptosis (Jang et al., 2017). This cell
suspension was then transferred to a 2 mL cryovial, which was frozen overnight at -80oC and
subsequently transferred to liquid nitrogen storage. The cryovial was kept in liquid nitrogen
storage until required for the invasion assay.
3.3 Original invasion assay (zero experiment)
3.3.1 Zero experiment
This invasion assay protocol is intended to be run with the addition of a drug molecule
expected to prevent bacterial infection. However, for our purposes we ran the assay without
adding a drug in order to obtain a baseline quantification of S. aureus infection of CHO cells as
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well as gain practice running the assay. Running the original assay also aided while we
brainstormed ideas for optimization. The zero experiment consisted of six samples: three with
fluorescent-stained bacteria, and three with unstained bacteria. The unstained bacteria samples
serve as a control to ensure that the fluorescent staining worked as expected, as well as to check
for possible cross-contamination. If successful, there will be a distinct difference between the
two sample conditions during flow cytometry analysis (Lu et al, 2007).
3.3.2 CHO cell plating and quantification
CHO cells were prepared the night before the invasion assay. Depending on the number
of samples needed for the assay, 2-4 10 cm plates of CHO cells at ~70-90% confluence were
trypsinized and collected in one tube. Cell suspension concentration was quantified using a
hemocytometer. For hemocytometer quantification, 15 µL of the cell suspension was added to an
Eppendorf tube containing 15 µL of 0.5% trypan blue solution, which helps assess cell viability.
The cells in each square of the hemocytometer were counted using a microscope set to 10X
magnification. CHO cell concentration was calculated using the following equation:
Total cells/well=

Total cell count∗initial volume of CHO cells∗dilution factor∗10 4
4

The cell suspension was split equally into the wells of one or more six–well tissue culture
plates, each of which contained 1 mL of growth medium. Each well received 0.5 mL of cell
suspension to bring the total volume to 1.5 mL. The plate(s) were incubated at 37oC overnight.
On the day of the invasion, the growth medium was removed from each well and replaced with 1
mL of DMEM.
3.3.3 RN4220 culture and quantification
S. aureus strain RN4220 was cultured in suspension the day before the invasion. [%] TSB
media was prepared by adding 1.5 g of TSB to 50 mL of DI water, and then autoclaving at 121oC
for 15 minutes. 4 mL of TSB media was added to each of four culture tubes, and one RN4220
colony was added to each using an inoculation loop. The tubes were incubated on a shaker at 225
rpm and 37oC for approximately 6 hours, then stored at 4oC overnight until the invasion. The
tubes were incubated under the same conditions for one more hour the morning of the invasion to
increase cell viability again after refrigeration. Each tube’s absorbance at 600 nm (OD600) was

21

measured, and ideally between ~0.4-1.0 to ensure that the bacteria are in the exponential phase of
their growth curve.
3.3.4 CFSE labeling of RN4220
Once confirmed to be within the optimal OD600 range, the S. aureus suspensions were
consolidated into two 15 mL falcon tubes and centrifuged at 5000 rpm for 10 minutes. The
supernatant was removed and each pellet was resuspended in 2 mL of PBS. Next, a 5 mM
carboxyfluorescein succinimidyl ester (CFSE) stock solution was prepared by adding 18µL of
DMSO to a separate vial of CFSE. This vial and all other vials containing the light-sensitive
fluorescent dye were wrapped in aluminum foil to protect the integrity of the dye and help
prevent photobleaching. One tube of bacteria was stained with 8µL of fluorescent dye and the
other tube was left unstained as the negative control. Both tubes were then incubated for one
hour on a shaker at 225 rpm and 37ºC.
After incubation, the bacterial cell culture tubes were centrifuged at 5000 rpm for 10
minutes. The unstained S. aureus pellet was resuspended with 2 mL of PBS, while the CFSEstained bacteria were washed three times with 2 mL of PBS using a cycle of centrifugation and
PBS resuspension. Finally, the OD600 of both tubes was measured to determine bacterial
concentration. The concentration of RN4220 in each tube was calculated using the following
equation:
Total bacteria cells /mL=OD 600× 8 ×108
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3.3.5 Invasion

Figure 9. Original invasion assay developed by Dr. Zhang’s lab (Lu et al, 2007).
In order to achieve notable and equal bacterial invasion, we calculated the volume of
bacteria cells that needed to be added to each well of CHO cells. To achieve a multiplicity of
infection (MOI) of 40, we used the equation below to calculate the volume of bacteria needed
from each tube.
Volume of bacteria needed =

Total CHO cells /well
Total bacteria cells /mL

The specified volume of unstained bacteria was added to three wells of the six-well plate,
while the other three wells received the specified volume of stained bacteria. The six-well plate
was then wrapped in tin foil and incubated at 37ºC for one hour. After being given sufficient
time to infect the CHO cells, the bacterial invasion was terminated by adding 6µL of gentamicin
to each well and incubating at 37oC for 45 minutes.
After termination, the CHO cells were washed with 2mL of PBS three times to remove
any debris and bacteria that didn’t invade the cells. The remaining CHO cells were then detached
using 0.5 mL of 0.25% Trypsin-EDTA and collected using 2 mL of growth medium. The cell
suspension collected from each well was placed in its own tube, with the tubes containing stained
samples being wrapped in aluminum foil. These six tubes were centrifuged at 1340 rpm for 5
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minutes, and the pellets were resuspended in 4% paraformaldehyde (PFA). PFA initiates crosslinking of the molecules within the infected cells, hardening the cell surface and preserving its
shape and contents (Kim et al., 2017). PFA fixation helps preserve cell structure before and
during flow cytometry analysis. Cells were resuspended in a volume of PFA solution that
resulted in a final concentration of 106 cells/mL and incubated at room temperature for 15
minutes. The samples were then spun down at 1340 rpm for 5 minutes. The supernatant was
discarded, and each sample was resuspended in 1 mL of PBS.
3.3.6 Flow cytometry
Flow cytometry analysis was performed using the BDTM Accuri C6 Plus flow cytometer.
The instrument was set to 10,000 events for all settings, then cleaned using 2 mL of FACS clean
solution (BD) and calibrated using 2 mL of DI water containing two drops of CS&T RUO beads.
Once successfully calibrated, 1 mL of each sample was pipetted through a CellTreat cell strainer
into a glass culture tube. The software was set to generate plots with FITC-A on the x-axis, and
the graphs were gated appropriately after running the first sample. A SIP clean step was
performed before running each sample to limit potential cross-contamination.
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3.4 Optimized invasion assay
3.4.1 Invasion

Figure 10. Our proposed optimization of the invasion assay.
The invasion portion of the experiment is intended to be performed almost exactly as
described in 3.3.4, with the elimination of a few steps. The CFSE labeling step is not necessary
in our optimized protocol, since we are analyzing genomic DNA rather than whole cells. The
PFA fixation step is also unnecessary for this same reason, since we want to release the nucleic
acids from inside the cells rather than keeping everything preserved inside. After collection and
centrifugation at the end of the invasion, the pellets will be resuspended in 1 mL of PBS and can
be stored at -80oC until use without significantly compromising DNA integrity (Kim et al, 2011).
3.4.2 qPCR reaction
Our optimized invasion assay uses quantitative polymerase chain reaction (qPCR) to
analyze infection efficiency rather than flow cytometry. The qPCR reaction consisted of the
reagents listed in Table 3 and followed the thermal cycler program described in Table 4. A BioRad CFX Connect thermal cycler was used for all experiments, and each sample was run in
triplicate to ensure consistent results.
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Table 3. qPCR reaction components
Reagent

Volume

Final concentration

SYBR Green Master Mix (2x)

5 µL

1x

Forward primer (10 µM)

1 µL

1 µM

Reverse primer (10 µM)

1 µL

1 µM

Sample

3 µL

Variable

.
Table 4. qPCR thermal cycler program.
Cycles

Temperature (oC)

Time

1

95

3 min

40

95

10 sec

60

20 sec

65

5 sec

1

3.4.3 Primer design
Multiple sets of primers were tested in order to troubleshoot non-specific amplification.
Primer sequences were either obtained from published work (Wood et al, 2021) or designed
using an online primer design program. We designed primers that individually targeted the 16S
rRNA, sortase A, and sortase B genes using Primer-BLAST (NCBI, “Primer BLAST”). The
specificity of these primer sequences for RN4220 was confirmed using Nucleotide BLAST
(NCBI, “Standard Nucleotide BLAST”), as well as the nonspecificity for the Chinese Hamster
genome.
3.4.4 Agarose gel electrophoresis
A 2% agarose gel was used for electrophoretic analysis in order to obtain better
resolution of smaller DNA fragments, as our expected PCR products were less than 300 bp in
length. 2% agarose was made by mixing 1 g of molecular biology grade agarose with 50 mL of
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1x TAE buffer. The solution was microwaved for 1 minute, and then again in 15 second intervals
until the agarose powder was completely dissolved. Once cool to the touch, 5 µL of Gelite™
Safe DNA Gel Stain was added to the solution. The solution was then poured into a gel mold,
and an 8-sample comb was inserted. The gel was allowed to sit for approximately 20 minutes,
after which the comb was removed and the gel was placed in the electrophoresis tank.
The tank was filled to the max line with a 1x TAE buffer, making sure that the agarose
gel was completely covered. Samples of interest were selected and mixed with 2 µL of 6x Purple
Gel Loading Dye (no SDS), then 10 µL of each were loaded into the gel. 10 µl of Quick-Load
Purple 1 kb Plus DNA Ladder was added to the first lane of the gel and used to determine
approximate fragment size. The electrophoresis tank was connected to a power source set to
output 120V, and was run for approximately 45 minutes or until the loading dye was ~2-3 cm
from the end of the gel. Gels were imaged using a UV gel imager from Azure Biosystems set to
302 nm, programmed for a 10 sec exposure.
3.4.5 qPCR data analysis
qPCR data was analyzed by looking at the Cq values of each sample. Data was prepared
in graph form by taking the reciprocal of each Cq value, so that increases and decreases in value
would be shown in a way that was easier to interpret visually.
3.5 Results
3.5.1 Zero experiment
Before beginning qPCR experiments, a “zero experiment” was run using the original
invasion assay protocol to establish a baseline for bacterial invasion in the absence of an
inhibiting drug molecule. The zero experiment protocol was established by Dr. Zhang’s lab in
2015. For this experiment, the BD Accuri™ C6 Plus Flow Cytometer was used to measure the
fluorescence intensity in samples of RN4220 S.aureus stained with CFSE dye and added to a sixwell plate containing CHO cells. Three wells represented our negative control which had CHO
cells infected with non-stained bacteria and the other three represented our positive control with
CHO cells infected with CFSE-stained bacteria.
We performed this experiment four times throughout the school year and were able to
gain success and valuable information from our final trial. The negative control seen in Fig. 11
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showed that the peak on the left and the gating indicate that 95.8% of the cells did not fluoresce,
which is expected of the non-stained bacteria. Fig. 12 indicates 52.1% of the bacteria in the
positive control was stained and had successfully invaded the mammalian cells. In order to better
understand the amount of bacteria within the CHO populations, we calculated the average uptake
index of each triplicate group and normalized it. These calculations were consistent with what
the flow cytometry graphs showed. Uptake index is a measurement of the bacterial
internalization and an indicator of sortase A activity on the cell membrane (Zhu et al, 2016);
uptake index is calculated by:
Uptake Index (UI) = Mean FITC-A * Percentage of Fluorescent Molecules
Table 5: Zero Experiment Calculations
Raw Data
Processed Data
FITC-A
Wells (Six- Mean FITCPercentage Uptake
Average Normaliz
Stained
well Plate)
A
of area (%) Index (UI)
UI
a%on
Percentage
A1
565.68
73.24
0.46 414.304032
Negave
Control, non- A2
stained
A3
B1
Posive
Control,
stained

B2

B3

3,387.42

40.91

1385.79352
5.14
2

2,676.00

35.55

0.82

54,971.66
141,801.80

53,722.23

951.318

917.13851 0.005092
8 325188

306.7

168598.081
52.07
2

145.68

206576.862
51.88
2

307.38

165131.390 180102.11
51.98
6
13

1
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Figure 11: Negative Control: Non-stained bacteria. The x-axis, FITC-A, represents the
fluorescent level from low to high. The y-axis represents the cell count.

Figure 12: Positive control: Stained bacteria. The x-axis, FITC-A, represents the fluorescent
level from low to high. The y-axis represents the cell count.
3.5.2 Primer optimization
3.5.2.1 16S rRNA gene primers
Initial experiments used primers targeting the 16S rRNA gene of S. aureus. The 16S
rRNA gene was selected because it is a popular target for bacterial quantification, and there are
several well-established qPCR assays for targeting it (Galazzo et al, 2020). While these primers
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did produce amplification in RN4220 samples, they also produced amplification in NTC samples
containing water instead of RN4220. This is likely because the 16S rRNA gene is present in all
bacterial genomes, and is relatively similar between species (Galazzo et al, 2020). Because of
this, any amount of bacterial contamination in the NTC samples would likely result in
amplification.
3.5.2.2 SaQuant primers
Because of the amplification seen in the NTC samples when using the 16S rRNA gene
primers, we decided to test primers specifically targeting S. aureus. We used primer sequences
from a published method for bacterial quantification using qPCR developed by Wood et al, titled
SaQuant. These primers had been optimized to be as specific for S. aureus as possible, which we
hoped would help reduce the amount of optimization time needed for our assay. The product
they produce is expected to be 73 bp long (Wood et al, 2021). While we used the primer
sequences presented in this paper, we did not use the same thermal cycler conditions; we utilized
a program confirmed to work by others in our lab. We also used SYBR Green for fluorescent
labeling of nucleic acids instead of probes.
These primers successfully amplified S. aureus genes without producing any
amplification in NTC samples. qPCR was also found to be sensitive enough to distinguish
between serial dilutions of S. aureus when using these primers (Fig.13). Previously prepared
invasion assay samples were also tested with these primers, and were found to have
amplification. However, amplification of a non-specific product was also produced in samples
containing only CHO cells (Fig 14.). Performing gel electrophoresis on these three samples
revealed a product in the samples containing CHO cells that was smaller than expected (Fig. 15).
These results raised questions about the specificity of our primers, and how well they were able
to successfully target S. aureus without amplifying mammalian genomes. It is critical that our
qPCR assay be able to distinguish between bacterial and mammalian genomes when analyzing
invasion assay samples, so further optimization was required.
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Figure 13. Relative amplification of serial dilutions of S. aureus.

Figure 14. Relative amplification of S. aureus, CHO cell, and invasion assay samples.
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Figure 15. Agarose gel showing PCR product sizes of S. aureus, CHO cell, and invasion assay
samples.
Primers were aligned with both the RN4220 genome and the Chinese Hamster genome
using Nucleotide BLAST (NCBI, “Standard Nucleotide BLAST”) to check for possible
specificity issues. Specificity was evaluated by comparing the E-values of each alignment. A
lower E-value correlates with a higher alignment, while a higher E-value correlates with a worse
alignment. Both the forward and reverse SaQuant primers were found to have high alignment
with the RN4220 genome and relatively low alignment with the Chinese hamster genome (Table
6), indicating that these primers should be specific for RN4220. This is contradictory to the
results we achieved during wet lab testing, and requires further investigation. However, it should
also be considered that the genome of the CHO cells we grow in our lab will likely be different
from the CHO cell genome recorded in online databases like NCBI.
Table 6. SaQuant primer alignment with the RN4220 and Chinese hamster genomes. Specificity
was evaluated by looking at the E-values of each alignment.
Primer

Genome

E-value

SaQuant (F)

RN4220

10-5

Chinese Hamster

3.6
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SaQuant (R)

RN4220

10-7

Chinese Hamster

7.3

3.5.2.3 Sortase A and Sortase B primers
New primer sets were designed in the hopes of eliminating the non-specific amplification
seen in samples containing CHO cells. One set targeted the sortase A gene and produced a 232
bp product, while the other targeted the sortase B gene and produced a 224 bp product. We chose
to target the sortase A gene because of its specificity to gram-positive bacteria and to get a closer
look at the potential inhibition mechanism of our small molecule drug. The sortase B primers
were chosen because they indicated a lower alignment to CHO cell lines than the sortase A
primers and we wanted to see if there was a significant difference in testing.
Table 7. Sortase A & sortase B primer alignment with RN4220 and CHO cell genomes.
Specificity was evaluated by analyzing the E-values of each alignment.
Primer

Genome

E-value

Sortase A (F)

RN4220

10-5

Chinese Hamster

4.6

RN4220

10-6

Chinese Hamster

5.5

RN4220

10-5

Chinese Hamster

18

RN4220

10-5

Chinese Hamster

4.6

Sortase A (R)

Sortase B (F)

Sortase B (R)
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Both sets of primers were tested on samples S. aureus, CHO, or invasion assay samples.
qPCR was run as before, and then samples were selected for gel electrophoresis analysis (Fig.
16). While the expected products were present in the S. aureus samples, they were not present in
the CHO cell or invasion assay samples. While this result makes sense for the CHO sample,
there are still nonspecific bands present on the gel. This is a problem because these amplicons
will show up as fluorescent during qPCR (due to the SYBR green), and make it difficult to
differentiate between CHO and S. aureus based on qPCR results alone. The invasion assay
samples also do not show the expected S. aureus product, which raises questions about whether
or not S. aureus was actually present in these samples to begin with. The success of the invasion
assay was not verified with fluorescence microscopy the day these samples were collected.

Figure 16. Gel electrophoresis analysis of samples amplified with either sortase A or sortase B
primers. Samples are compared to a 1 kbp Plus ladder.
While not successful at completely eliminating nonspecific amplification, both sets of
primers do work in S. aureus and produce the expected product. These preliminary results
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suggest that our primer design may not be the issue, and that we should examine our reaction
conditions and experimental samples.
3.5.3 Cell lysis optimization
Cell lysis conditions were optimized to ensure enough DNA was present for the iTaq
polymerase to amplify. Initial experiments compared samples of RN4220 at a concentration of
106 cells/mL with no preparation, heat treatment, a freeze-thaw cycle, and lysozyme treatment
plus freeze-thaw cycle. Heat treatment was performed by heating 20 µL of RN4220 at 95ºC for
10 minutes, while freeze-thaw cycle was performed by freezing 20 µL of RN4220 at -80ºC for
10 minutes and then immediately heating at 95ºC for 10 minutes. Lysozyme treatment involved
the addition of 2 µL of lyophilized lysozyme (Bio-Rad, “PCR Troubleshooting”) to 20 µL of
RN4220, then the completion of a freeze-thaw cycle as described above. The samples treated
with lysozyme did not show any amplification, which we hypothesized could be due to
interference of the enzyme with the PCR reaction. There were no significant differences in
amplification between the baseline samples, the heat treated samples, and the freeze-thaw cycle
samples when analyzing our preliminary data (unpaired t-test, p>0.05) (Fig. 17).
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Figure 17. Effect of sample preparation methods on relative amplification. Differences between
Cq values of the different treatment methods were not significant (unpaired t-test, p>0.05).
A detergent-based lysis buffer was also tested as part of this optimization. 0.5%, 1%, 2%,
5%, and 10% solutions of Triton X-100 were prepared by diluting with nuclease-free water
(Ambion). 1 ml aliquots of RN4220 were spun down at 5000 RPM for 10 min, then resuspended
in one of the prepared lysis buffers. Triton X-100 lysis buffer was found to produce inconsistent
Cq values as well as abnormal-looking amplification curves in some samples (Fig. 18). These
results suggested that may Triton X-100 interfere with the qPCR reaction, and that it may be
better to use samples of RN4220 that had not been prepared with detergent-based lysis buffers.
More aggressive lysis methods were not attempted because sufficient amplification was obtained
without them, and also because these methods are more time-consuming. The goal of this
optimization was to reduce the time needed to perform the invasion assay.
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Figure 18. Comparison of amplification curves with 0% (top left), 1% (top right), and 10%
(bottom) Triton X-100. These graphs are representative of a majority of the samples from this
experiment.
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Chapter 4: Discussion and Future Directions
4.1 AI
There are many components and facets of the AI which have room for growth. Due to the
youth of the field and expense of software tools, there were significant barriers to the
development and research of the system. While our tool did provide advantages in a limited
scope, a more complete system which automates the next step of fragment combination would
significantly raise the value of the system. This was infeasible due largely to a lack of training
data: while data on the structures of small molecule fragments was available, reliable ground
truth data on how they would interact with sufficient complexity was sparse. This left a gap in
the research which should be investigated by a later project. However, our research was meant to
establish the potential for this method of drug design. So while there are some aspects for which
further research is required, that goal was accomplished.
In terms of future directions, there are three major directions of future software research
we would recommend pursuing. These are automatic fragment combination, new target
selection, and the creation of a GUI. Each of these would yield enormous benefits to the
software’s usage, in different ways.
Automation of fragment combination is the logical next step in the AI’s progression. The
industry software tools which would enable this were beyond our budget scope, but it is
theoretically possible and would be another huge step forward in accelerating the drug design
process. An equally potent step forward would be attempting to replicate the process we
undertook with targets other than Sortase A. There exist hundreds if not thousands of dangerous
proteins which an effective binding molecule could defang, and approaches like the one we
tested here could be the solution.
4.2 Invasion assay optimization
Despite being specific for the RN4220 genome and not for Chinese hamster genome
during Nucleotide BLAST analysis, both the SaQuant primers and the sortase A/B primer sets
appeared to produce non-specific amplicons when CHO cells were present in the sample. One
possible reason for this is contamination of our CHO cell samples, though this seems unlikely
since the CHO cells we used appeared to be clean at the time of trypsinization. It is also possible
that there is a sequence in the Chinese hamster genome that is similar to the region of S. aureus
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that our primers target. The next question to answer is how to decrease the nonspecific binding
of primers to and amplification of this Chinese hamster sequence.
Perhaps the next logical step to troubleshoot this issue is to run the same set of
experiments using a different mammalian cell line, such as HEK293. This would help us
determine whether or not the nonspecific amplification was the result of a sequence in the CHO
cell line genome. Another possible step could be to vary primer concentration, since the Bio-Rad
troubleshooting page suggests that using a high concentration of primers can increase the
chances of nonspecific amplification. They suggest that primer concentration be in the range of
0.2-1 µM, and we are at the high end of the range with a concentration of 1 µM (Bio-Rad, “PCR
Troubleshooting”).
One last way to troubleshoot could be the addition of common PCR additives such as
DMSO, bovine serum albumin (BSA), and/or glycerol, which have been shown to help improve
the sensitivity and specificity of qPCR reactions (Wang et al, 2015; Sedgley et al, 2005). If
neither primer dilution nor the addition of common PCR additives are effective, two slightly
more complex directions could be using a commercially-available hot-start DNA polymerase
(Green et al, 2018; ThermoFisher Scientific, “How is Hot-Start Technology Beneficial For Your
PCR?”) or performing a nested PCR reaction (van Pelt-Verkuil et al, 2008; Tran et al, 2014).
Once optimal specificity has been achieved and optimized for detecting S. aureus in
samples containing CHO cells, we hope to implement our protocol with the invasion assay. We
would first run a baseline experiment with no drug molecule to ensure that S. aureus can be
detected as expected. This baseline experiment would still involve the fluorescent staining of
RN4220 before the invasion, so that successful infection can be confirmed via fluorescent
microscope. The next experiment would be one that mimics a successful drug without adding
another layer of complexity to the protocol. It would follow the same protocol as the baseline
experiment, except each condition would get a different number of S. aureus cells. The original
protocol calls for 40x the number of CHO cells in the sample, so we may try 40x, 30x, 20x, and
10x. This experiment would allow us to determine whether or not our assay is sensitive enough
to detect differences in the amount of bacteria present in different samples. The final step would
be to test our protocol with a drug molecule that is already known to inhibit sortase A and
prevent infection, to see if our assay can detect a difference between samples treated with
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different concentrations of this drug. These results could be compared to flow cytometry results
to give us an idea of how accurate our quantification is.
Though we still have a ways to go in terms of optimizing the invasion assay, we have
made good progress on primer optimization and gained important insights on possible ways to
improve our protocol. If successful, this optimized protocol would significantly improve the
amount of time and labor required for testing potential drug candidates. This project has made
small but important steps towards the development of successful anti-infective drugs, an
alternative treatment method against bacterial infections that addresses the growing crisis of
microbial antibiotic resistance.
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Chapter 5: Engineering Standards and Realistic Constraints
5.1 Science, Technology, and Society
With decreasing effectiveness of antibiotic drugs due to the increasing resistance of
bacteria, anti-infective drugs will become much more important and urgent in the coming years
as they deal with drug-resistant strains of bacteria (O’Neill, 2014). Antibiotics only work to kill
off bacteria inside a person who has already been infected, which allows any bacteria which
survive the drugs to become a drug resistant strain of bacteria. Anti-infective drugs prevent this
issue entirely by preventing bacteria from infecting a host, which also prevents the bacteria from
developing a resistance to the drugs by disabling their ability to reproduce.
An issue of public concern is the decreasing effectiveness of existing drugs to combat
bacteria. As part of our engineering responsibility to civic engagement, we chose to tackle this
project. The SARS-CoV-2 pandemic and the increasing frequency of pandemics and epidemics
in general have demonstrated the degree to which pandemics strain resources which are
important to the development of drugs to combat the outbreaks. Research into BioAI will make
the urgent development of drugs much faster, easier, and cheaper, potentially allowing for the
mitigation of future pandemics.
5.2 Ethical Considerations
While there are numerous goods which could potentially come from this project and from
the design process it follows, there is a strong potential for misuse. The ability to design a
compound for interaction with a specific protein could lead to the creation of poisonous and
toxic compounds which could cause severe and widespread harm if left in the wrong hands.
There are several realities that must be considered in evaluating the danger of this process to
limit the danger of this model of BioAI.
For the vast majority of malicious actors, this project would be entirely irrelevant. First
and foremost, this model requires chemical and biological knowledge to develop drugs, which
are not commonly held by amateurs. This BioAI requires a singular protein to target, so even if a
group of malevolent actors got a hold of this technology, without experienced molecular biology
experts, lab technicians, and expansive laboratories, they would not be able to put it to effective
use. Without those resources and specialists, it would be impossible to select an effective protein
target. The significant danger from this BioAI then, is exclusively large-scale organizations who
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are seeking to target particular proteins and have access to huge research, testing, and
manufacturing capabilities. While such organizations exist, they almost certainly have existing
weaponry which makes the risk of this project causing additional harm minimal. For example, if
the BioAI is capable of producing a compound which is equally harmful as the nerve agent VX,
a prospect which sounds terrifying, it would actually cause little to no harm. The group using the
chemical agent could have simply produced VX, which has a publicly known structure, and been
no less dangerous for it. Therefore the BioAI would not increase the harm of those actors.
A large number of toxins and chemical weapons are already public knowledge just like
VX, and those would be faster and cheaper to produce as the design phase would be entirely
skipped. While it is possible that the BioAI could produce more toxic compounds than VX, it is
unlikely that malicious actors would choose to waste so many resources for incremental gains.
Thus this AI pragmatically is of little use to dangerous actors, given the scale of publicly
available toxins. So while the BioAI being able to create unique chemical threats is an extant
possibility, it is an unlikely case which is outweighed by the consistent good anti-infective drugs
it would create in medical care. So while security of data and toxins ought to be maintained as
much as possible to control the risk as much as possible, the potential for misuse is not a reason
to stop research in this field.
5.3 Usability and Sustainability
The physical testing of chemicals consumes chemical reagents, as well as often safety
equipment and lab time. It is far more energy and resource efficient to instead test them in silica.
Both in terms of ease for technologists and for reducing chemical waste, AI drug development
presents a clear improvement in usability and sustainability as compared to traditional drug
design. Furthermore, optimization of the invasion assay used for testing anti-infective drugs in
vitro to use qPCR instead of flow cytometry improves the assay’s usability, making it
significantly easier to run and decreasing the amount of time required for troubleshooting.
5.4 Health and Safety
An important thing to consider is that drug candidates will not escape the normal scrutiny
of drug proposals just because they are designed by a computer. The usual multi-year process of
testing and clinical trials will be enacted, and this will severely limit the potential damage which
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drug candidates algorithmically generated will be able to produce. Drug candidates will undergo
in vitro testing with immortalized cell lines, and then will be tested in vivo using mouse or other
animal models. If the drug candidate does well in both of these tests, it can advance to the
clinical trial phase where its safety and efficacy will be tested in human patients. The drugs
produced by the BioAI program do not have an innately higher risk than those designed by
typical human testing methods, so once the drug candidate reaches this stage, it is ethically
indistinguishable from classically developed drug candidates.
Another important ethical aspect of drug development and human testing is upholding
informed consent. One of the most important aims for our research is not only to create an AI
program and wet lab protocol that is safe, but also transparent and easy to understand. Our
advisor and entire research group take the saying “Make sure your grandma can understand!”
into our research, especially when it comes to ethical considerations. If human subjects are
unaware of the process that is responsible for their experimental treatment and the risks involved,
there is no point in testing and the ultimate goal of our research is considered failed. Great strides
in medicine have almost always been made with informed consent and by ethical standards based
on the ultimate goal of improving health and quality of life. Although the process of initial
design is different, the same standards and principles of drug testing such as accessibility, which
apply to all drug design, can be implemented here, ensuring continued ethical practice and as
little medical risk as possible.
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Appendix A: Healthy vs. contaminated CHO cell culture
(A) Healthy CHO cells

(B) CHO cells contaminated with bacteria
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Appendix B: qPCR Primer Sequences

Primer

Sequence

16S rRNA (F)

CTGGAACTGAGACACGGTCC

16S rRNA (R)

TGCCACCTACGTATTACCGC

SaQuant (F)

AACTACTAGGGGAGCCTAATRAT

SqQuant (R)

GGTACTAACCAAATCAGGTCATAA

Sortase A (F)

CGTTTTTCCCAAACGCCTGT

Sortase A (R)

ACACTTTCATTGACCGTCCGA

Sortase B (F)

ACAAGCAAGAACGCGCAAAT

Sortase B (R)

ACGTCGATGTTCTCGCTCAA
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